Immunomedics' Trodelvy Will Be First ADC For Triple-Negative Breast Cancer
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.
Trodelvy was granted an accelerated approval by the US FDA based on a Phase II study. It is the first commercial product for Immunomedics.